Polyarteritis Nodosa (Cutaneous Type)

Comprehensive Medical Guide: Cutaneous Polyarteritis Nodosa (CPAN)

1. Introduction & Overview

Cutaneous Polyarteritis Nodosa (CPAN) represents a localized, non-systemic form of necrotizing vasculitis that primarily affects the medium-sized arteries of the dermis and subcutaneous tissues. Unlike Systemic Polyarteritis Nodosa (PAN), which involves visceral organs such as the kidneys, gastrointestinal tract, and nervous system, CPAN is restricted to the skin and occasionally the peripheral nerves or joints.

Clinically, it manifests as a chronic, relapsing condition characterized by tender subcutaneous nodules, livedo reticularis, and painful ulcerations. While it lacks the life-threatening visceral involvement associated with systemic vasculitis, it remains a debilitating condition that requires careful clinical management to prevent chronic ulceration and skin necrosis.

2. Etiology and Pathophysiology

The precise etiology of CPAN remains idiopathic in a significant percentage of cases. However, current research highlights a complex interplay between genetic predisposition, environmental triggers, and immune-mediated vascular injury.

The Pathogenetic Mechanism

The hallmark of CPAN is necrotizing vasculitis. The process follows a specific sequence:
1. Triggering Event: Often linked to post-streptococcal infections, hepatitis B/C, or drug-induced hypersensitivity.
2. Immune Complex Deposition: The formation of antigen-antibody complexes leads to the activation of the complement cascade.
3. Endothelial Injury: Neutrophil infiltration of the arterial wall (leukocytoclastic vasculitis) leads to fibrinoid necrosis.
4. Ischemia: The inflammation causes narrowing of the vessel lumen, leading to downstream tissue ischemia, resulting in the characteristic nodules and ulcers.

3. Clinical Staging and Grading

While there is no universally standardized "staging" system for CPAN like there is for cancer, clinicians typically grade the severity based on the Cutaneous Vasculitis Activity Score (CVAS).

• Stage I (Early/Mild): Isolated subcutaneous nodules, minimal livedo reticularis, no ulceration.
• Stage II (Moderate): Persistent nodules, worsening livedo, superficial ulceration, localized pain.
• Stage III (Severe/Chronic): Deep necrotizing ulcers, extensive skin necrosis, secondary bacterial infection, systemic symptoms (fever/arthralgia).

4. Standard Clinical Presentation

Patients typically present with a chronic, relapsing course. The onset is insidious, and the condition often persists for months or years.

• Subcutaneous Nodules: These are the hallmark. They are firm, tender, and range from 0.5 to 2 cm in diameter. They are most frequently located on the lower extremities (calves, ankles, and feet).
• Livedo Reticularis: A violaceous, net-like discoloration of the skin caused by the impairment of blood flow in the dermal plexuses.
• Ulcerations: Often develop over the nodules. These ulcers are typically painful, shallow, and have a "punched-out" appearance.
• Constitutional Symptoms: While restricted to the skin, patients may report low-grade fever, malaise, and arthralgias (joint pain), which are common in inflammatory vasculitis.

5. Differential Diagnosis

Distinguishing CPAN from other vasculitides is critical. The following table highlights key differentials:

6. Key Diagnostic Tests

Diagnosis is primarily clinical, supported by histological evidence.

1. Skin Biopsy (Gold Standard): An excisional wedge biopsy is preferred over a punch biopsy to reach the deep dermal/subcutaneous arteries. Histology reveals segmental necrotizing vasculitis of medium-sized arteries.
2. Laboratory Workup:
   • Inflammatory Markers: ESR (Erythrocyte Sedimentation Rate) and CRP are often elevated.
   • Infection Screening: Streptococcal titers (ASO), Hepatitis B/C serology.
   • Autoimmune Profile: ANA (Antinuclear Antibody) and ANCA (usually negative in CPAN).
3. Imaging: If systemic involvement is suspected, CT angiography or MR angiography of the abdomen is required to rule out renal or mesenteric artery aneurysms.

7. Risks, Side Effects, and Contraindications

The treatment of CPAN typically involves anti-inflammatory and immunosuppressive agents.

• Standard Therapy: Colchicine (first-line for mild cases), Dapsone, or Pentoxifylline.
• Corticosteroids: Used for acute flares but contraindicated for long-term use due to side effects (osteoporosis, hyperglycemia, weight gain).
• Immunosuppressants (Methotrexate/Azathioprine): Used for refractory cases. These carry risks of bone marrow suppression and hepatotoxicity.
• Contraindications: Systemic immunosuppression should be avoided if there is an active, untreated underlying infection (e.g., latent TB or viral hepatitis).

8. Long-Term Prognosis

CPAN generally has an excellent prognosis compared to systemic vasculitis. It is not life-threatening. However, the disease is notoriously chronic and relapsing.

• Morbidity: Chronic pain and permanent skin scarring from ulcers are the primary issues.
• Remission: Many patients achieve long-term remission with aggressive initial treatment, though some require low-maintenance doses of medication for years.
• Monitoring: Regular follow-ups are essential to ensure the condition does not "evolve" into systemic PAN, although this is rare (less than 5% of cases).

9. Frequently Asked Questions (FAQ)

1. Is Cutaneous Polyarteritis Nodosa a form of cancer?
No. CPAN is an autoimmune-mediated inflammatory condition of the blood vessels. It is not a malignancy.

2. Can CPAN turn into Systemic PAN?
While rare, it is possible. This is why patients are regularly monitored for blood pressure changes, abdominal pain, or neurological symptoms.

3. What is the most common trigger for CPAN?
Streptococcal infections are the most frequently identified trigger, particularly in pediatric populations.

4. Does CPAN cause permanent nerve damage?
In some cases, the inflammation of vessels supplying the nerves (vasa nervorum) can cause localized sensory deficits, though this is less severe than the systemic form.

5. How effective is Colchicine in treating CPAN?
Colchicine is highly effective for many patients, acting as an anti-inflammatory that stabilizes the neutrophils. It is the preferred starting point due to its safety profile.

6. Are there specific diets that help with CPAN?
There is no specific "vasculitis diet," but an anti-inflammatory diet (rich in Omega-3s and antioxidants) is generally recommended to support overall immune health.

7. Is the biopsy procedure painful?
It requires a local anesthetic. Because the nodules are often tender, the procedure is performed with care, but it is the only way to confirm a diagnosis definitively.

8. Can I exercise with active CPAN?
Moderate exercise is encouraged, but activities that put excessive pressure on the legs (like heavy impact running) may aggravate ulcers. Consult your rheumatologist for activity guidelines.

9. Why do my ulcers take so long to heal?
The ulcers are caused by a lack of blood supply (ischemia) due to the underlying vasculitis. Healing is slow because the tissue is not receiving adequate oxygen and nutrients until the vasculitis is controlled.

10. Is CPAN hereditary?
There is no clear evidence of direct inheritance, though genetic markers related to immune system regulation may play a role in susceptibility.

10. Conclusion

Cutaneous Polyarteritis Nodosa is a distinct, non-systemic vasculitis that demands a methodical approach to diagnosis and a patient-centered approach to treatment. While the condition is benign in terms of mortality, its impact on quality of life—due to pain, ulceration, and the chronic nature of the disease—cannot be understated. Through the use of targeted anti-inflammatory therapies and diligent monitoring, most patients can achieve excellent symptomatic control and maintain a high quality of life.

Disclaimer: This guide is for educational purposes and does not constitute medical advice. Always consult with a board-certified rheumatologist or dermatologist for clinical diagnosis and management.